Main Article Content
Aims: Mucinous, medullary, and papillary carcinomas are rarely encountered types of breast cancer. This study aims to contribute to the literature by comparing the clinical and prognostic features and treatment alternatives of rare breast carcinomas.
Study Design: Thirty-four patients with rare breast cancer out of a total of 1368 patients who underwent surgery for breast cancer in our clinic between January 2011 and December 2020 were included in the study.
Methodology: The patients were assigned into three groups, i.e., medullary carcinoma group (Group 1), mucinous carcinoma group (Group 2) and papillary carcinoma group (Group 3). Demographic and clinical features, treatment modalities used, surgical approaches, pathological features of tumors and survival were compared between the groups.
Results: Thirty-four patients were included in the study. The mean age of the patients in Group 3 was higher, though it was not statistically significant. Modified radical mastectomy was more frequently performed in all the groups. The number of the lymph nodes removed through axillary dissections and the number of the positive lymph nodes were similar in all the groups. The tumors in all the groups were also of comparable sizes (30 mm in Group 1, 42.5 mm in Group 2 and 30 mm in Group 3; p:0.464). Estrogen receptors were negative in a significantly higher rate of Group 1(66.7% of Group 1, p<0,001). A significantly higher rate of Group 1 received postoperative chemotherapy (93,3% of Group 1,p:0.001), but the rate of the patients receiving hormonotherapy in this group was significantly lower (26.7% of Group, p<0,001). The patients with medullary cancer had significantly longer survival than those with mucinous cancer and those with papillary cancer (76.2 in Group 1, 54.5 in Group 2 and 58.4 in Group 3; p:0.005).
Conclusion: While rare subtypes of breast carcinoma did not affect opting for surgical treatment, selection of oncological therapy was affected depending on the hormone receptor status of these tumors. The long-term survival differed between rare breast tumors. In view of the unique clinical pictures of the tumors, the patients should be evaluated individually, and the evaluation should be associated with theevidence-based principles available for more common breast carcinomas.
Solanki M, Visscher D. Pathology of breast cancer in the last half century. Hum Pathol. 2020;95:137-148. DOI: 10.1016/j.humpath.2019.09.007
Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35. DOI: 10.1097/PAP.0000000000000232
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019;69(1):7-34. DOI: 10.3322/caac.21551
Erdogan O, Yuksel U M, Berberoğlu U, Gulben K, Aksel B, Uyar O et al. The accuracy of memorial sloan-kettering cancer center nomogram in anatolian breast cancer patients. Acta Oncol Tur. 2016;49(3):151-157. DOI: 10.5505/aot.2016.04127
Türkyılmaz M, Hacıkamiloğlu E, Deniz EB, Boztaş G, Dündar S, Ergün AK, et al. Türkiye Kanser İstatistikleri 2015. TC Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Ankara; 2018.
Breast Cancer, Turkey. In: WHO, editor.: GLOBOCAN 2018, International Agency for Research on Cancer; 2018.
Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma--rare types: review of the literature. Ann Oncol. 2009;20(11):1763-70. DOI: 10.1093/annonc/mdp245.
Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press Breast Cancer Research. 2004;6:133.
Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI et al. Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. Cancer Causes Control. 2019;30(1):31-39. DOI: 10.1007/s10552-018-1121-1.
Gupta I, Sareyeldin RM, Al-Hashimi I, Al-Thawadi HA, Al Farsi H, Vranic S, et al. triple negative breast cancer profile, from gene to microrna, in relation to ethnicity. Cancers (Basel). 2019;13;11(3):363. DOI: 10.3390/cancers11030363
Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C, Kern F et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Sci Rep. 2018;2;8(1): 11584. DOI: 10.1038/s41598-018-29917-2
Lai J, Wang H, Pan Z, Su F. A novel six-microRNA-based model to improve prognosis prediction of breast cancer. Aging (Albany NY). 2019;30;11(2):649-662. DOI: 10.18632/aging.101767
Gök M, Topal U, Öz B, Akgün H, Akcan AC, Sözüer EM. Comparison of clinical features and treatment results of mix mucinous carcinomas and other atypical carcinomas of the breast. Eur J Breast Health. 2019;1;15(4):222-228. DOI: 10.5152/ejbh.2019.5032
Yıldırım N, Aldemir MN, Şimşek M, Bilici M, Tekin SB. Nadir Meme Tümörleri. Bakırköy Tıp Dergisi 2019;15:232-9. DOI:10.4274/BTDMJB.galenos.2019.20180815080623
Poirier É, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J et al. Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast. J Surg Oncol. 2018;117(6):1137-1143. DOI: 10.1002/jso.24944.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168.
Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score conversion table. Histopathology. 2008;53:346–347. DOI: 10.1111/j.1365-2559.2008.03075.x
Masood S. Breast cancer subtypes: morphologic and biologic characterization. Women’s Health (Lond). 2016;12(1):103-19. DOI: 10.2217/whe.15.99.
Dumitru A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache M et al. Mucinous breast cancer: a review study of 5 year experience from a hospital-based series of cases. Maedica (Bucur). 2015;10(1):14-8. .
Zheng YZ, Hu X, Shao ZM. Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: A seer population-based study. Sci Rep. 2016;7;6:24037. DOI: 10.1038/srep24037
Han Y, Wang J, Xu B. Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. Breast. 2020;54:114-120. DOI: 10.1016/j.breast.2020.09.006
Vo T, Xing Y, Meric-Bernstam F, Mirza N, Vlastos G, Symmans WF et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007;194(4):527-31. DOI: 10.1016/j.amjsurg.2007.06.012